ALKS Alkermes plc

Stifel reiterated $ALKS Buy-$63 and said -- We are reiterating our Buy rating on ALKS following positive signals in the ph1b from ALKS 7290, their orexin agonist for ADHD. CNTA - $LLY $TAK SUPN OTSKY AXSM Stifel added—In the 2wk study in ADHD patients, '7290 demonstrated AISRS reductions from baseline of 14/19points for the 20/50mg dose cohorts, and a 1-2point reduction in CGI-S, which, for 2 week efficacy, looks strong in the context of other studies (better than Strattera, nearing stimulants). The important caveat here though is that we do not know how this compares to placebo (which was not disclosed in the PR); we followed up with ALKS who emphasized that there were only 8 placebo completers here in what was a small (N = 50) study where patients were 4:1 randomized to active or placebo. We assume the placebo effect was significant, but big picture we still think orexins have real potential in ADHD, given the data and also validating precedent from other narcolepsy drugs.

Stifel reiterated $ALKS Buy-$63 after hosting the Co's CEO Blair Jackson and IR Sandy Coombs on an NDR on the West Coast. CNTA - $LLY $TAK OTSKY AXSM SUPN Stifel said in its note: Recall, Mr. Jackson has recently transitioned into the CEO role after serving as COO at ALKS--the focus continues to be on scaling growth at Alkermes. Key takeaways from the meetings were: (1) continued confidence in the upcoming Vibrance-3 ph2 readout in IH this year, where management is looking to show a clear benefit on ESS and IHSS, (2) observation of strong enrollment in the NT1/NT2 Brilliance ph3s--where we may see topline data as early as next summer, (3) confidence in the commercial opportunity and positioning of alixorexton, and (4) enthusiasm around the early profile of ALKS 7290, where management highlighted the consistent response across endpoints in the ADHD ph1b. Bottom line: after a pullback, we think the stock is attractive here ahead of various catalysts.

Healthcare dip-pullback scan (6 Oct) $ALKS $HCSG $CLYM $IKT: all 17–40% off 52W highs, with MACD histogram rising 2+ bars and RSI turning up from the 30s–40s. Entry trigger: buy only on a break above the prior day's high, with volume above average. Stop: below the recent swing low. No trigger, no trade. Dip bought on confirmation, not on a falling knife. 📈 Not financial advice. #swingtrading #healthcare

$ALKS Phase 1b data in ADHD looks good. Strong potential here if their drug helps executive dysfunction it could be used for autism too

$ALKS price action a bit concerning for pending ALKS 7290 readout. Still see value in alixorexton especially for NT2/IH.